The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Highmobility group box 1 (HMGB1), a DNAbinding cytokine expressed mainly by macrophages, contributes to lesion progression and chronic inflammation within atherosclerotic plaque. It has been suggested that different cytokines could regulate HMGB1 expression in monocytes. We have analyzed the effect of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) on HMGB1 expression both in vivo and in vitro. Methods and Results-Expression of TWEAK and its receptor fibroblast growth factor-inducible 14 (Fn14) was positively correlated with HMGB1 in human carotid atherosclerotic plaques. TWEAK increased HMGB1 mRNA expression and protein secretion in human acute monocytic leukemia cell line cultured monocytes. TWEAKmediated HMGB1 increase was only observed in M1 macrophages but not in M2 ones. These effects were reversed using blocking anti Fn14 antibody or nuclear factorkappa B and phosphotidylinositol3 kinase inhibitors. TWEAK also increased monocyte chemoattractant protein1 secretion in human acute monocytic leukemia cell line cells, an effect blocked with an HMGB1 small interfering RNA. Systemic TWEAK injection in ApoE −/− mice increased HMGB1 protein expression in the aortic root and mRNA expression in total aorta of ApoE −/− mice. Conversely, TWEAKblocking antibodies diminished HMGB1 protein and mRNA expression compared with IgGtreated mice. Conclusion-Our results indicate that TWEAK can regulate expression and secretion of HMGB1 in monocytes/ macrophages, participating in the inflammatory response associated with atherosclerotic plaque development.
A therosclerosis is a chronic inflammatory disease charac terized by accumulation of atherogenic lipoproteins, extracellular matrix, vascular smooth muscle cells (VSMCs), and inflammatory cells. It is known that cytokines within atherosclerotic plaques play an important role in the progression of atherosclerosis. 1, 2 Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a recently described member of the tumor necrosis factor superfamily, which is initially synthesized as a type II membranebound protein and is processed quickly into a smaller, soluble fragment, which mediates the different biological properties of this molecule. 3 Interaction of TWEAK with its receptor, the fibroblast growth factor-inducible 14 (Fn14), induces a high number of physiological and pathological processes depending on cell type and environment. 4 TWEAK is expressed at high levels in intestine, pancreas, heart, lung, brain, ovary, vasculature, and skeletal muscle, and at lower levels in liver and kidney. 3, 4 In contrast, Fn14 is expressed at low levels or is absent in healthy tissues. Within the vasculature, TWEAK is expressed in normal nonatherosclerotic arteries, while its receptor is absent. 5, 6 However, both TWEAK and Fn14 are expressed in different areas of human atherosclerotic plaques colocalizing with VSMCs and macrophages. 5 TWEAK-Fn14 interaction is implicated in several processes associated with atherosclerotic plaque development, such as inflammation, 7 proliferation and migration of vascular cells, 8 thrombosis, 9 and angiogenesis. 8, 9 In this context, it has been demonstrated that TWEAK enhances vascular lesions associated with hyperlipidemia in apolipoprotein E (ApoE) knockout mice by exacerbating secretion of proinflammatory cytokines favoring macrophage recruitment. 10 These data indicate that Fn14-TWEAK interaction takes place in the diseased vessel wall, which may have adverse outcomes in atherosclerotic lesion progression. [10] [11] [12] On the other hand, highmobility group box 1 (HMGB1) is a highly conserved and ubiquitous protein mostly expressed in the nuclei of cells. HMGB1 is released from necrotic cells 13 and activated macrophages. 14 After binding to the receptor for advanced glycation end products or to tolllike receptor 4, HMGB1 activates vascular endothelial cells and macrophages/ monocytes to express proinflammatory cytokines, chemokines, and adhesion molecules functioning as a critical mediator of inflammation and promoting tissue repair and regeneration. 15 Different studies have demonstrated that HMGB1 plays a piv otal role in cardiovascular diseases. 16 HMGB1 is expressed in human atherosclerotic plaques. 14 In vitro, HMGB1 increases proliferation and migration of VSMCs and macrophages 17 and induces endothelial cell activation. 18 Finally, it has been recently reported that treatment with an antiHMGB1 neu tralizing antibody diminished atherosclerotic lesion size and inflammation in ApoE knockout mice. 19 Several cytokines such as tumor necrosis factorα or interferonγ can regulate HMGB1 expression and secretion by macrophages. 14 However, the relation between TWEAK and HMGB1 secretion has been minimally analyzed 14 and the in vivo modulation of HMGB1 by TWEAK has not been explored. In the present study, we examined the effect of TWEAK-Fn14 interaction on HMGB1 expression and secretion in cultured monocytes. In addition, we analyzed the association of both proteins with HMGB1 in human carotid atherosclerotic plaques. Furthermore, we have determined the effect of recombinant TWEAK or antiTWEAK neutralizing antibody treatment on HMGB1 expression in atherosclerotic plaques of hyperlipidemic ApoE knockout mice.
Materials and Methods

Reagents
Roswell Park Memorial Institute medium1640, penicillin, and strep tomycin were obtained from BioWhittaker. Fetal bovine serum was from Gibco. Recombinant soluble human TWEAK (rHuTWEAK) was from Millipore, and mouse antihuman Fn14 blocking antibody (ITEM2) was from eBioscience. A blocking murine antiTWEAK mouse monoclonal antibody (mAb) (clone P2D10) was generated in TWEAK −/− mice that crossreacts with human TWEAK. The generation of mAb and TWEAKblocking activity was previously described. 10 This antibody and nonspecific IgG were generously gifted by Biogen Idec. The remaining reagents were obtained from Sigma unless specified otherwise.
Cell Culture
Human monocytic cell line human acute monocytic leukemia cell line (THP1) (ATCC; TIB202) was cultured in Roswell Park Memorial Institute medium supplemented with 10% decomplemented fetal bovine serum, 2 mmol/L glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, at 37°C in 5% CO 2 . To stimulate HMGB1 expression in THP1 monocytes, cells were plated at 2×10 6 cells/mL in Roswell Park Memorial Institute medium1640 supplemented with 0.5% fetal bovine serum. Cells were treated with different concentrations of TWEAK for 24, 48, 72 and 96 hours. To investigate the involvement of various signaling pathways in regulating HMGB1 expression, cells were pretreated for 1 to 2 hours with various protein kinase or nuclear factorkappa B (NFκB) inhibitors and then treated with TWEAK for 72 hours. HMGB1 concentration in cell supernatants was then assessed by Western blot analysis.
RNA Extraction and Real-Time Polymerase Chain Reaction
Total RNA from THP1 or aorta from mice was obtained by TRIzol method (Life Technologies) and quantified by absorbance at 260 nm in duplicate. Realtime polymerase chain reaction (RTPCR) was performed on a TaqMan ABI 7700 Sequence Detection System using heatactivated TaqDNA polymerase (Amplitaq Gold). After an initial hold of 2 minutes at 50ºC and 10 minutes at 95ºC, the samples were cycled 40 times at 95ºC for 15 seconds and 60ºC for 60 seconds. 18S rRNA served as the housekeeping gene and was amplified in parallel with the genes of interest. The expression of target genes was normalized to housekeeping transcripts. All probes and reagents were obtained from Applied Biosystems. All measurements were performed in duplicate. Values of each sample were obtained as mul tiples of their baseline values.
Western Blot
Cells from different experimental conditions were collected and pel leted. Western blots of cellular or supernatant proteins were analyzed as previously described. 20 The blots were incubated with antihuman HMGB1 antibody (Abcam, UK), IκBalpha (sc371, Santa Cruz), βactin (sc47778, Santa Cruz), phospho (p)protein kinase B (AKT) (sc7985, Santa Cruz), AKT (sc8312, Santa Cruz), p(extracellular signalregulated kinase) ERK (sc7383, Santa Cruz), and ERK (sc 154, Santa Cruz). Quantification was expressed as arbitrary densi tometric units.
Transfection of Small Interfering RNA
THP1 cells were transfected with the Cell Line nucleofector Kit V, program V001 (Amaxa) according to the manufacturer's instructions. The HMGB1 and control small interfering RNA were from Applied Biosystems. Transfections were incubated for 72 hours before add ing recombinant TWEAK to obtain maximal transfection efficiency (around 60%).
Animal Model
Twentyfour ApoE knockout mice (16 weeks of age) were fed on a hyperlipidemic diet (21.2% fat (0.15% cholesterol) + 16.7% proteins) for 10 weeks. After that, animals were randomized into 4 groups: mice injected IP with saline (control group n=6), human recombinant TWEAK (0.01 mg/kg per day, n=6), antiTWEAK mAb (1 mg/kg per day, n=6), or nonspecific IgG (1 mg/kg per day, n= 6) daily for 9 days. The dose of TWEAK was chosen based on earlier in vivo studies 21 and the dose of antiTWEAK mAb was chosen to be 100fold in excess of the TWEAK dose. Anesthetized mice were saline perfused. The aortic root was embedded in optimal cutting temperature and frozen for immunohistochemistry. Total aorta was frozen until mRNA was extracted. The study was performed in accordance with the European Union normative and was approved by the ethical committee of our institution. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication no. 85-23, revised 1996).
Patients
Twentyfive patients undergoing carotid endarterectomy at Hospital GaldakaoUsansolo (Spain) with asymptomatic carotid stenosis (>70%) were included in the study (22 men and 3 women, 73±6 years old, 52% hyperlipidemic, 28% diabetic, 88% hypertensive patients, and 24% smokers). The region of the bifurcation of the common carotid artery was chosen. Atherosclerotic plaques were collected at the time of the surgery and storage in the Biobank of IISFundación Jiménez Díaz. Informed consent was obtained before enrollment in all cases. The study was approved by the hospital's ethics committee (Hospital GaldakaoUsansolo, Spain) according to the institutional and the Good Clinical Practice guidelines. The study was performed in accordance with the principles outlined in the Declaration of Helsinki, and all participants gave written informed consent.
Immunohistochemistry
Human carotid atherosclerotic plaques were stored in parafor maldehyde for 24 hours and later in ethanol until paraffin embed ded. Plaques were crosssectioned into 5µmthick pieces, dewaxed and rehydrated, and incubated overnight with antiHMGB1 (1:200 dilution; Abcam), antiTWEAK (1:100 dilution; R&D Systems), antiFn14 (1:200 dilution; Cell Signaling Technology), antiCD68 (1:100 dilution; Dako), antialpha actin (1:100 dilution; Dako), and antiCD163 (1:100 dilution; Serotec). Negative controls using the corresponding IgG were included to check for nonspecific staining. Biotinylated secondary antibodies were applied for 1 hour. Then, an avidin-biotin peroxidase complex (Vectastain ABC kit; Vector Laboratories) was added for 30 minutes. Sections were stained with 3amino9ethylcarbazole (Dako), counterstained with hematoxylin, and mounted in Pertex.
Mice aortic roots were crosssectioned into 4µmthick sec tions. Primary antibody was rabbit antiHMGB1 (1:200 dilution). Donkey antirabbit biotin was used as secondary antibody and then ABComplex-horseradish peroxidase was added. The immuno histochemistry sections were stained with 3,3'diaminobenzidine (Dako), counterstained with hematoxylin, and mounted in Kaisers Glyceringelatine (Merck).
For immunofluorescence studies, THP1 cells were plated onto Labtek slides, fixed in 4% paraformaldehyde, and permeabilized in 0.2% Triton X100/PBS, washed in PBS, and incubated with rabbit antiHMGB1 (1:100), followed by fluorescein isothiocyanate second ary antibody. Nuclei were counterstained with propidium iodide or 4',6diamidino2phenylindole.
Quantification
Computerassisted morphometric analysis with the Olympus semi automatic image analysis system Micro Image software (version 1.0 for Windows) was performed by a pathologist who was blinded to the group of patients to which the atherosclerotic plaques belonged, as previously described. 5 Results are expressed as per mm 2 for human plaques or per μm 2 for animal plaques.
Statistical Analysis
Statistical analysis was performed using SPSS 11.0 statistical soft ware. Univariate association was performed by Pearson correlation test. In vitro experiments were replicated at least 3 times. Results are expressed as mean+SD. Significance at the P<0.05 level was assessed by Student t test for 2 groups of data and ANOVA for 3 or more groups. Differences were considered significant at a value of P<0.05.
Results
Association Among HMGB1, TWEAK, and Fn14 Expression in Human Carotid Atherosclerotic Plaques
We have analyzed the possible relationship among HMGB1, TWEAK, and Fn14 expression in atherosclerotic plaques. TWEAK and Fn14 were highly expressed in positive areas for VSMCs (αSMactin + ) and macrophages (CD68 + ), whereas HMGB1 was mainly expressed in macrophagerich areas within human atherosclerotic plaques ( Figure 1A) . Moreover, analysis of HMGB1, TWEAK, and Fn14 expression in serial sections of atherosclerotic plaques revealed a highly positive linear correlation between HMGB1 and Fn14 expression (r=0.616; P<0.001) or HMGB1 and TWEAK expression (r=0.526; P=0.034). These positive associations remain significant when we only consider the shoulder region of atherosclerotic plaques, which is characterized by a high content of infiltrat ing macrophages ( Figure 1B) . However, when we analyzed the relationship between these variables in the cap (the rim over the atherosclerotic core), the association was not significant for HMGB1 and Fn14 (r=−0.008; not significant), or HMGB1 and TWEAK (r=0.089; not significant). Overall, our results could indicate that the TWEAK-Fn14 axis could participate in the regulation of HMGB1 expression in the vascular wall. 
TWEAK Increases HMGB1 Expression and Secretion in Cultured THP-1 Monocytes
Because HMGB1 is associated with TWEAK in macro phagerich areas of human atherosclerotic plaques, we stud ied whether TWEAK can modulate HMGB1 expression and protein secretion in cultured THP1 monocytes. For this, THP1 cells were cultured in the absence or presence of dif ferent concentrations of recombinant human TWEAK, and HMGB1 mRNA expression was analyzed. RTPCR revealed that TWEAK increased HMGB1 mRNA expression in a dose and timedependent manner (Figure 2A ), peaking at 6 hours. HMGB1 is predominantly expressed in the cell nucleus and, after stimulation of its expression, is released to the cytoplasm and then secreted to the conditioned medium. For this reason, we have analyzed HMGB1 secretion in culture supernatants. TWEAK increased HMGB1 content in the culture medium in a dose and timedependent manner over 96 hours ( Figure  2B and 2C). Similar results were obtained in cultured human monocytes ( Figure I in the onlineonly Data Supplement).
To determine the implication of the TWEAK recep tor, Fn14, in the signaling mechanism underlying HMGB1 induction by TWEAK, we have analyzed the effect of anti Fn14 blocking antibodies on HMGB1 secretion induced by TWEAK. Preincubation with blocking antibody against Fn14 prevented HMGB1 secretion induced by TWEAK ( Figure   2C ). No effect was observed when cells were incubated with nonspecific IgG ( Figure 2C ).
Regulation of HMGB1 Cellular Localization by TWEAK
It has been demonstrated that different cytokines can modulate the cellular distribution of HMGB1 in human monocytes. 14 To determine whether TWEAKinduced HMGB1 secretion also affects its cellular distribution, cultured THP1 cells were immu nostained with antiHMGB1 antibodies and counterstained with propidium iodide. Control cells constitutively expressed HMGB1 mostly localized in the nucleus ( Figure 2D ). Incubation of THP1 cells with TWEAK induced a redistribution of HMGB1 from the nucleus to the cytoplasm ( Figure 2D ). In contrast, pre treatment of cells with blocking antibody against Fn14 prevented TWEAKmediated redistribution of HMGB1 in the cells.
TWEAK-mediated Effects on HMGB1 Expression Are Restricted to Proinflammatory Macrophages In Vitro and in Human Carotid Atherosclerotic Plaques
It has been reported that the polarization of monocytes toward inflammatory (M1) or alternatively activated (M2) macro phages skews the secretion of HMGB1. 22 To determine whether the effects of TWEAK on HMGB1 expression depends on the macrophage subtype, we performed in vitro studies where THP1 cells were differentiated to M1 or M2 by using phrobol is mainly restricted to the nuclei [counterstained by propidium iodide (PI), red] as shown by yellow representing colocalization. THP-1 cells exposed to TWEAK for 2 days contained high amounts of HMGB1 in their cytoplasm with less protein localized in the nuclei. In contrast, THP-1 cells treated with TWEAK and anti-Fn14 showed nuclear HMGB1 distribution.
12myristate 13acetate or phrobol 12myristate 13acetate plus dexamethasone, respectively. 23 After that, M1 and M2 derived macrophages were stimulated with recombinant TWEAK to ana lyze HMGB1 mRNA expression. RTPCR showed that HMGB1 was expressed by both M1 and M2 macrophages. Treatment with recombinant TWEAK increased HMGB1 mRNA expres sion in M1 macrophages, but not in M2 macrophages ( Figure  3A ). In the same way, TWEAK increased HMGB1 content in culture supernatant from M1 macrophages, but not from M2 macrophages ( Figure 3B ), indicating that the effect observed after TWEAK treatment is specific for M1 macrophages. We then analyzed the expression of HMGB1 in human ath erosclerotic plaques according to the macrophage subtype. Double immunostaining for HMGB1 and CD68 (a marker expressed in both M1 and M2 macrophages) revealed that in some cells HMGB1 was observed in the nuclei, whereas in other macrophages, no HMGB1 was observed or HMGB1 was not colocalized within the nuclei. Double immunostain ing for HMGB1 and CD163 (an M2 marker) showed that HMGB1 remained mainly in the nucleus of M2 macrophages, suggesting that no release of HMGB1 occurred in these anti inflammatory cells. Overall, these data could indicate that M1 macrophages are responsible for HMGB1 secretion in human atherosclerotic plaques.
Regulation of TWEAK-Induced HMGB1 Secretion in Monocytes
TWEAK can modulate different signaling pathways, such as ERK1/ERK2, phosphotidylinositol3 kinase/AKT (PI3K/ AKT), and NFκB, a transcription factor implicated in the regulation of the proinflammatory response. 21, 24 We exam ined whether these kinases and this transcription factor might contribute to the augmented HMGB1 secretion. As shown in Figure 4A , TWEAK increased ERK1/ERK2 and AKT phos phorylation in a timedependent manner. In addition, TWEAK induced a diminution in IκB protein, indicating an activation of NFκB. Preexposure to PD98059 (an ERK1/ERK2 inhibitor) did not affect the ability of TWEAK to elevate HMGB1 secre tion ( Figure 4B ). In contrast, wortmannin (an inhibitor of PI3K/ AKT pathway) and parthenolide (a NFκB inhibitor) attenu ated the elevation in HMGB1 secretion induced by TWEAK ( Figure 4B ). To analyze whether PI3K/AKTmediated effects were independent of the NFκB effects, we pretreated THP1 cells with wortmannin and parthenolide alone or in combina tion, both at higher or lower doses. No additive or synergistic effects on attenuation of the elevation in HMGB1 secretion induced by TWEAK were observed ( Figure 4C ). Thus, PI3K/ Akt and NFκB, but not ERK1/ERK2, regulate TWEAK induced elevations in HMGB1 secretion by monocytes.
HMGB1 Is Involved in TWEAK-Mediated MCP-1 Release
To analyze whether the increment in HMGB1 expression induced by TWEAK may contribute to the inflammatory response, we first analyzed proinflammatory monocyte chemoattractant pro tein1 secretion in supernatants of THP1 cells that were cultured in the presence or absence of TWEAK. We observed that soluble MCP1 was augmented in a time and dosedependent manner in the culture medium from THP1 cells after TWEAK treatment ( Figure 5A and 5B ). In these experimental conditions, anti Fn14 antibody reversed the proinflammatory response induced by TWEAK ( Figure 5B ). In addition, we analyzed the MCP1 content in supernatant medium in HMGB1 small interfering RNA-transfected THP1 cells. Silencing of HMGB1 completely prevented longterm MCP1 release induced by TWEAK in monocytes ( Figure 5C ). No effect was observed when cells were incubated with control small interfering RNA ( Figure 5B ).
TWEAK Modulates HMGB1 mRNA and Protein Expression in Atherosclerotic Plaques From ApoE Knockout Mice
We have previously demonstrated that systemic TWEAK injec tion increases inflammation and lesion size in hyperlipidemic ApoE knockout mice. 10 Using the same animal model, ani mals injected with TWEAK showed an increment in HMGB1 expression in atherosclerotic plaques present in the aortic root compared with animals injected with saline (28+4.9% positive staining of total area versus 16±2.7%, respectively; P<0.05; Figure 6A ). In addition, mice treated with an antiTWEAK mAb showed reduced HMGB1 expression compared with control and nonspecific IgGinjected mice [7±1.2 (anti TWEAK) versus 16±2.7 (control); or 14±1.9 (IgG); P<0.05]. These results were confirmed by quantitative RTPCR analysis of HMGB1 mRNA expression from total aorta ( Figure 6B) . These results suggest that endogenous TWEAK may play a role in HMGB1 expression within the arterial wall in vivo.
Discussion
In the present work, we have shown that HMGB1 expres sion is positively associated with Fn14 and TWEAK within human carotid atherosclerotic plaques. Furthermore, TWEAK administration induces HMGB1 expression and secretion in cultured THP1 monocytes. Finally, systemic injection of recombinant TWEAK augmented HMGB1 expression in atherosclerotic plaques of hyperlipidemic ApoE −/− mice. The involvement of endogenous TWEAK in plaque inflammation was also demonstrated by reduced HMGB1 expression after shortterm treatment with antiTWEAK neutralizing mAb in ApoE −/− mice. The TWEAK-Fn14 axis has been described as a media tor of different processes within the arterial wall. Both are involved in many processes during the development of ath erosclerotic plaques, such as proliferation, inflammation, angiogenesis, and apoptosis. 11 Both TWEAK and Fn14 are expressed in human atherosclerotic plaques by VSMCs and macrophages. 5 HMGB1 is also expressed by both cell types, 25 the macrophages being the major source of HMGB1 in human atherosclerotic plaques. 14 Now, we have observed a positive association among HMGB1, TWEAK, and Fn14 expression in the shoulder region of human atherosclerotic plaques, an area characterized by high macrophage content. These data could indicate that TWEAK is implicated in the regulation of HMGB1 within pathological vessel walls. In this respect, we have observed that TWEAK increased HMGB1 expression and secretion in THP1 cultured monocytes. As reported with other molecules, such as lipopolysaccharide, interferonγ, TGFβ, and tumor necrosis factorα, 14 TWEAK treatment promoted HMGB1 release being apparent after 48 hours of incubation. Interestingly, TWEAKmediated HMGB1 secre tion was related to the presence of Fn14. Thus, use of an anti Fn14 blocking antibody prevented the increment observed in HMGB1 secretion. These data indicate that the TWEAK-Fn14 axis regulates HMGB1 expression in monocyte/macrophages.
Macrophages comprise heterogeneous cell populations, including inflammatory/M1 and antiinflammatory/M2 mac rophages, which can be identified based on their phenotypic characteristics. 26 Macrophage polarization may vary depend ing on the nature of the environment. 27 M1 cells infiltrate injured tissues at earlier times after damage, increasing proin flammatory response, whereas M2 macrophages predominate during the resolution phases and show important antiinflam matory properties. 28 In a previous study, it was reported that polarization of monocytes toward M1 or M2 macrophages skews the secretion of HMGB1. 22 Our data support this obser vation because TWEAK increased HMGB1 mRNA expres sion and protein secretion in M1 macrophages, suggesting that TWEAK may be involved in the promotion of inflam matory response associated with M1 macrophages throughout HMGB1 release. HMGB1 secretion appeared to be associated with both transient elevation in its mRNA levels and translocation from the nucleus to the cytoplasm. 14 In this sense, we have also observed that HMGB1 mRNA upregulation induced by TWEAK was followed by migration of HMGB1 protein from the nucleus to the cytoplasm. In addition, intracellular levels of HMGB1 remained constant (not shown), indicating that release of HMGB1 was accompanied by an augmentation of HMGB1 synthesis.
It is known that HMGB1 expression is regulated by ERK1/2, PKC, and PI3K/Akt. 14 Because TWEAK-Fn14 exerts many of its actions through ERK1/2 or PI3K/Akt, 21 we analyzed the effect of PD098059 (ERK1/2 inhibitor) and wortmannin (PI3K/Akt inhibitor) on HMGB1 secretion induced by TWEAK. Although TWEAK augmented ERK1/2 phosphorylation in THP1 cells, no effect was observed when PD098059 was added to the culture medium on HMGB1 secretion. In contrast, PI3K inhibitor reduced HMGB1 secre tion induced by TWEAK. These data indicate that PI3K, but not ERK1/2, is a specific signal implicated in the control of HMGB1 release induced by TWEAK in monocytes.
In contrast to the effect observed with other cytokines, 14 we have shown that NFκB is specifically implicated in the regu lation of HMGB1 secretion by monocytes. Using an inhibitor of this transcription factor, parthenolide, HMGB1 secretion induced by TWEAK was diminished. Different studies have demonstrated that the TWEAK-Fn14 axis exerts many of its actions through NFκB activation in different cell types. [29] [30] [31] Moreover, TWEAK increases NFκB activation in athero sclerotic plaques present in the aortic root of ApoE knockout mice. 10 The finding that NFκB can regulate HMGB1 release induced by TWEAK is important because secreted HMGB1 may in turn induce NFκB activation 18 raising the possibil ity that a loop exists between NFκB and HMGB1, which prolongs the vascular proinflammatory effects associated with TWEAK. 11 In fact, once released into the intravascular space, HMGB1 could potentially amplify local inflammatory responses by enhancing the release of cytokines and chemo kines from monocytes-macrophages. 32 Moreover, HMGB1 interacts with endothelial cells by upregulating surface recep tors and inducing the secretion of soluble proinflammatory mediators. HMGB1 also induces the release of a large array of inflammatory cytokines, including tumor necrosis factorα, MCP1, and interleukin6. 18, 32 Now, using a HMGB1 small interfering RNA, we have observed that HMGB1 mediates MCP1 release induced by TWEAK in monocytes/macro phages. These data could demonstrate that HMGB1 is the mediator of the chronic inflammatory response induced by TWEAK. It is important to note that although the TWEAK/ Fn14 system appears to induce HMGB1 expression through NFκB and PI3/AKT pathways, we could not exclude the fact that other pathways may be involved in the regulation of HMGB1 expression by the TWEAK-Fn14 axis. Finally, we have observed that ApoE −/− mice injected with recombi nant TWEAK showed an increased HMGB1 expression in total aorta and in atherosclerotic plaques present in the aor tic root. Moreover, blocking antibodies against TWEAK showed ≈ 50% reduction in HMGB1 expression in athero sclerotic plaques and total aorta in comparison with control mice, demonstrating that, an antiTWEAK therapy might be useful to modulate HMGB1 expression in atherosclerotic plaques. However, there are many factors regulating HMGB1; our data also suggest that the remaining HMGB1 expression observed after antiTWEAK therapy may be induced by other pathway(s) different from the TWEAK-Fn14 axis. Moreover, it has been demonstrated that blocking either TWEAK or HMGB1 by neutralizing antibodies diminishes development of atherosclerosis in ApoE knockout mice. 10, 19 In both cases, neutralizing antibodies decreased proinflammatory cytokine expression and macrophage recruitment in mice atheroscle rotic plaques. The similar response observed with both neu tralizing antibodies suggests that harmful effects induced by TWEAK may be related, at least in part, to HMGB1.
In conclusion, the present study reveals a novel role of TWEAK in vascular disease, by enhancing HMGB1 expres sion and participating in the inflammatory response associated with atherosclerotic plaque development. 
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